ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Biophytis SA

Biophytis SA (BPTS)

8.22
0.00
(0.00%)
Closed May 29 4:00PM
0.00
0.00
(0.00%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
8.22
Bid
7.91
Ask
8.96
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
8.22
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
1,040,482,000
Dividend Yield
-
PE Ratio
-72,439.02
Earnings Per Share (EPS)
-0.02
Revenue
-
Net Profit
-17.03M

About Biophytis SA

Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Paris, Paris, Fra
Founded
1970
Biophytis SA is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BPTS. The last closing price for Biophytis was $8.22. Over the last year, Biophytis shares have traded in a share price range of $ 0.00 to $ 0.00.

Biophytis currently has 1,040,482,000 shares outstanding. The market capitalization of Biophytis is $1.24 trillion. Biophytis has a price to earnings ratio (PE ratio) of -72439.02.

BPTS Latest News

Biotech Catches Major Premarket Bid Following Financial Results

A Paris-based biotech company is turning heads so far during Tuesday’s premarket after the company reported year-over-year FY23 EPS results, according to a press release To read the full...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.08M
AWINAERWINS Technologies Inc
$ 8.99
(139.10%)
5.41M
INSMInsmed Inc
$ 48.107
(118.67%)
33.42M
GVVisionary Holdings Inc
$ 0.38
(90.00%)
10.33M
SOBRSOBR Safe Inc
$ 0.41
(82.22%)
130.83M
APDNApplied DNA Sciences Inc
$ 0.580601
(-70.82%)
9.46M
LUCYInnovative Eyewear Inc
$ 0.40
(-59.31%)
85M
MRAIMarpai Inc
$ 0.90
(-53.61%)
803.83k
TOIIWOncology Institute Inc
$ 0.021
(-52.60%)
293.22k
SHOTWSafety Shot Inc
$ 0.21
(-36.07%)
24.26k
PEGYPineapple Energy Inc
$ 0.2595
(45.70%)
676.68M
GWAVGreenwave Technology Solutions Inc
$ 0.0782
(-7.89%)
306.67M
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.08M
CRKNCrown Electrokinetics Corporation
$ 0.1073
(6.24%)
232.62M
OBLGOblong Inc
$ 0.21
(19.32%)
146.15M

BPTS Discussion

View Posts
Renee Renee 1 month ago
BPTS changed to BPTSY. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
BPTS new 52 week lo
πŸ‘οΈ0
Renee Renee 1 month ago
BPTS: Effective April 23,2024 a one for 40 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
BPTS new 52 lo
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
Wash trade underway
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
Wash trade underway
πŸ‘οΈ0
81vette 81vette 3 months ago
with no sign of reversal
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
BPTS new 52=week low
πŸ‘οΈ0
81vette 81vette 5 months ago
Daily chart>ubb@.82(above is parabolic)sma50@.7655(breakout above until the dma50@.8438)then breakout to parsar @.98 that would signal bullish run start to the sma200@2.13
πŸ‘οΈ0
81vette 81vette 5 months ago
And .6501 too,ok that’s enough for me,sniper school 101 β€œbuild a position and wait patiently to shoot β€œ lol and with this garbage β€œwhen you get a good/safe shot,take it,a better one might not come β€œ
πŸ‘οΈ0
81vette 81vette 5 months ago
Come on fill my .70s to add to my .71s
πŸ‘οΈ0
81vette 81vette 5 months ago
Hopefully not before I sell tomorrow,lol,whatever you do,don’t look at the financials (you will vomit in your lap,lol)but they do have 6.2m cash,so maybe no offer to destroy pps tomorrow (maybe) 1for 10 r/s in March again before the June delist deadline(they will keep milking this cash cow)
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
It will be delisted in 2024
👎️ 1 🤡 1 🩳 1
81vette 81vette 5 months ago
Hopefully it’s a slow leak,lol,yesterday 41k dump (usually the remainder of a debt/dilution) total garbage fins so this is just a take 100% win and run to the bank play
πŸ‘οΈ0
81vette 81vette 5 months ago
Accumulation Fri.0046,now .2299 up 50Xs on no event,some ppl know something,bought and are holding,the fins. Are absolutely horrible (the only good thing I see is eps up 87% this year,target price $9.48, but that doesn’t make a hill of beans)
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
A rising tide lifts all boats, including the leaking ones
👎️ 1 💩 1 🤡 1
81vette 81vette 5 months ago
ZERO BORROW 571% fee,in past has gapped and ran next day,usually news
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
BPTS new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
BPTS under $2
πŸ‘οΈ0
INV4 INV4 8 months ago
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

Mon, September 25, 2023

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, and Skyepharma, a French pharmaceutical company specializing in the formulation, development and production of pharmaceutical products, announce the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19, with a view to the submission of marketing authorization applications.

Based on the active ingredient produced by SEQENS, Skyepharma will develop finished product batches meeting the GMP (Good Manufacturing Practice) standards required for market access filings. The key stages in the production of Sarconeos (BIO101) will be entrusted to leading, innovative French partners meeting the highest standards of pharmaceutical quality. Pharmaceutical development work at the industrial stage will complete the information required for early access authorizations, particularly in France and Brazil.

Stanislas Veillet, CEO of Biophytis, states: "Following on from the framework contract signed with SEQENS in July for the production of Sarconeos active ingredient (BIO101), this new partnership is a key step for Biophytis as it secures the production of finished product batches of its leading drug candidate, and thus continues our efforts to access our targeted markets."

David Lescuyer, CEO of Skyepharma, added: "We are delighted to be working alongside Biophytis to develop the regulatory batches for Sarconeos (BIO101). We are also proud to have approvals from the world's leading health agencies - the FDA in the United States, the EMA in Europe and ANVISA in Brazil - enabling us to ensure the marketing and commercial production of Sarconeos (BIO101) in these countries. For us, it's a question of putting our expertise at the service of ambitious projects capable of solving major public health issues."

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. Sarconeos (BIO101), our lead drug candidate, is a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory (Covid-19) diseases. Promising clinical results were obtained in the treatment of sarcopenia in an international phase 2 study, enabling the launch of a phase 3 study in this indication (SARA project). The safety and efficacy of Sarconeos (BIO101) in the treatment of severe COVID-19 were studied in a positive international phase 2-3 clinical trial (COVA project). A pediatric formulation of Sarconeos (BIO101) is currently being developed for the treatment of Duchenne Muscular Dystrophy (DMD, MYODA project). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040).

For more information, visit www.biophytis.com

About SKYEPHARMA
Skyepharma is an independent French pharmaceutical CDMO company, 100% owned by its management team and Bpifrance. Skyepharma specializes in the formulation, development and production of oral pharmaceutical products (tablets, capsules, powders), with particular expertise and proprietary technologies for complex and modified-release forms. Skyepharma is based in Saint-Quentin-Fallavier (Isère), near Lyon international airport. Skyepharma develops and manufactures drugs for international clients, supported by proprietary technologies and a site certified by the European (ANSM), American (FDA) and Brazilian (ANVISA) authorities, among others.

Through Skyehub Bioproduction, Skyepharma also offers clinical and commercial production capabilities dedicated to biomedical companies.

For further information, visit www.skyepharma.com

https://finance.yahoo.com/news/biophytis-skyepharma-sign-partnership-agreement-053000201.html

$BPTS
πŸ‘οΈ0
subslover subslover 8 months ago
YEA! Nice going dande!
πŸ‘οΈ0
dande1990 dande1990 8 months ago
Nice alert!! In at 1.22 out at 1.38.

$BPTS
πŸ‘οΈ0
Invest-in-America Invest-in-America 8 months ago
BPTS: Maybe a PR looming about their anti-Covid cocktail.
πŸ‘οΈ0
subslover subslover 8 months ago
Pre-market action.
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
BPTS new 52 week low
πŸ‘οΈ0
subslover subslover 10 months ago
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that it has received a positive opinion from Belgian authorities to conduct its SARA-31 program, which will be the first phase 3 study ever launched in sarcopenia.

The launch of the Phase 3 program follows the promising results obtained in the SARA-INT Phase 2b study, and the scientific advice given in 2022 by the EMA (European Medicine Agency), which helped define the conditions for starting such a study in Europe, specifying the Phase 3 protocol. Final authorization depends on a positive opinion from the Ethics Committee in Belgium. A similar application has been filed with the FDA (Food and Drug Administration) to start this study in the United States, with a response expected in the coming weeks. Further authorizations may be requested in other countries, depending on the needs of the study.

Stanislas Veillet, Chief Executive Officer of Biophytis, commented: "This opinion is a major step forward in our efforts to treat sarcopenia, an age-related neuromuscular disease characterized by the progressive loss of muscle strength and walking in the elderly, leading to loss of autonomy and reduced life expectancy. Despite the enormous medical need posed by this disease, no drug is currently approved anywhere in the world. Today, we are putting our pioneering position in this field into practice by obtaining, for the first time, a positive opinion from a regulatory agency to conduct a phase 3 clinical trial in this debilitating geriatric disease, which affects more than 30 million patients worldwide".

About SARA-31

The aim of phase 3 is to evaluate the efficiency and safety of Sarconeos (BIO101) in the treatment of sarcopenic patients at risk of motor disability. Around 900 patients aged over 65 with severe sarcopenia (3 ≤ SPPB ≤ 7) with low walking speed (4-meter walking speed ≤ 0.8 m/s) and low grip strength (HGS < 20kg for women and < 35.5 kg for men) will be included. They will be treated for a minimum of 12 months and a maximum of 36 months, receiving either placebo or 350mg of Sarconeos (BIO101) twice daily. The main criterion will be an assessment of the risk of Major Mobility Disability (MMD), measured by the ability to walk 400m in less than 15 minutes. This main criterion will be supplemented by the following secondary criteria: walking speed (4-m walking speed from the SPPB - Short Physical Performance Battery - test), grip strength (HGS) and patient-reported quality of life (Patient Reported Outcome SarQol, a questionnaire specifically developed for sarcopenia).

Roger A. Fielding, PhD, sarcopenia expert and laboratory director at Tufts University, Boston, will be the principal investigator of the SARA-31 study. He is continuing his contribution to the Sarconeos (BIO101) clinical development program in this indication.

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. Sarconeos (BIO101), our lead drug candidate, is a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory (Covid-19) diseases. Promising clinical results were obtained in the treatment of sarcopenia in an international phase 2 study, enabling the launch of a phase 3 study in this indication (SARA project). The safety and efficacy of Sarconeos (BIO101) in the treatment of severe COVID-19 were studied in a positive international phase 2-3 clinical trial (COVA project), enabling the preparation of conditional marketing authorization (CMA) applications in Europe and Emergency Use Authorization (EUA) applications in the United States. A pediatric formulation of Sarconeos (BIO101) is currently being developed for the treatment of Duchenne Muscular Dystrophy (DMD, MYODA project). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040).

For more information, visit www.biophytis.com

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of wordssuchas"outlook,""believes,""expects,""potential,""continues,""may,""will,""should,""could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward- looking statements are based on assumptions that Biophytis considers to be reasonable.However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which re subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» sectionfromtheCompany's2022FinancialReport available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Biophytis contacts

Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com

Media

Antoine Denry:antoine.denry@taddeo.fr - +33 6 18 07 83 27
πŸ‘οΈ0
Awl416 Awl416 10 months ago
Why?
πŸ‘οΈ0
harry crumb harry crumb 10 months ago
5+ coming
πŸ‘οΈ0
AJ Freely AJ Freely 10 months ago
$BPTS - Up 58% Pre-Market/ Current Price $3.53
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

1:20 am ET July 18, 2023 (Accesswire) Print
PARIS, FRANCE / ACCESSWIRE / July 18, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases and SEQENS, integrated global player in solutions and ingredients for the pharmaceutical and specialty markets, offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty products, announced the conclusion of a master agreement for the production of the active compound in Sarconeos (BIO101), Biophytis' main drug candidate developed for three indications: severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.

SEQENS will produce the active ingredient in Sarconeos (BIO101) in France at its Villeneuve La Garenne plant, near Paris. This historic site was modernized and expanded in 2020 with the opening of a unit to produce high-potential active pharmaceutical ingredients (APIs). The production center is equipped with state-of-the-art infrastructures in line with SEQENS' commitments to decarbonization and employee health and safety.
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
Scumbags thieves RS’d the stock, should be taken off the exchange for good! Ass…..!
👍️ 1
harry crumb harry crumb 1 year ago
Accumulation now, break out coming! $$$$
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
BPTS: A classic NO-Brainer --- & I qualify on THAT score --- if there ever was one, Boss!!! (But, I just got a NEW Brain, last week!! See me below, just after surgery, enjoying an HPCO Hemp-Rolled cig.!!)

πŸ‘οΈ0
subslover subslover 1 year ago
Thank you, MR McGurn!
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
Like i said this has some huge upside moving forward, not your typical little bio stock here. Worthy of buying an holding
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
BPTS: Here it is, & plenty of it.
https://www.asktraders.com/analysis/biophytis-bpts-stock-rallied-47-on-positive-clinical-trial-results/
https://investorplace.com/2023/03/why-is-biophytis-bpts-stock-up-28-today/
https://stockhouse.com/news/press-releases/2023/03/09/biophytis-to-present-positive-results-of-phase-2-3-cova-study-at-ers-2023-21st
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
This could be a huge runner folks
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
10 million in float?
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
Whats the float an OS, thanx
πŸ‘οΈ0
FORDGT FORDGT 1 year ago
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
πŸ‘οΈ0
subslover subslover 1 year ago
We're up 44% pre-market. Don't see news. Maybe it's on the way?
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
What’s with all these 6k’s, holy smokes. Stock has some volume
πŸ‘οΈ0
81vette 81vette 1 year ago
lots of ppl were selling after holding for long time,now they gone and we have higher high breakout into close,after market could/should continue to go up (100%+gap up today means huge possible tomorrow)then French market opens at 3am EST,if it goes up we do also(they are 6hrs ahead) the two mkts feed off each other if our after mkt does well their open does well and our pre mkt does well,(France doesnt have a pre or post market,orders are accepted and queued early but dont go thru until open)
πŸ‘οΈ0
vintagesake vintagesake 1 year ago
it had terrific volume and ran nice PM....what's the problem with it here during market hours??
πŸ‘οΈ0
81vette 81vette 1 year ago
quadruple bottom(60min)above .71 is breakout,traded double the market cap so far(insane)next few days/weeks pps will catch up,many waiting for gap fill thats not going to happen>French mother ticker closed up 48%(gap never filled) old bagholders and most who wanted out are out by now,institutional buying should start tomorrow and send BPTS skyward,this is the best looking ticker this year and i nailed a 700% win(it looks 3Xs better)
πŸ‘οΈ0
Box Money Box Money 1 year ago
Get it on a little dip here. Once this thing gets market approval it’ll be 10 bucks.
πŸ‘οΈ0
81vette 81vette 1 year ago
no shares to short,fee>205.34% 0.00% 0 2023-02-02 12:15:03
205.34% 0.00% 0 2023-02-02 12:00:04
205.34% 0.00% 0 2023-02-02 11:45:04
205.34% 0.00% 0 2023-02-02 11:30:04
205.34% 0.00% 0 2023-02-02 11:15:03
205.34% 0.00% 0 2023-02-02 11:00:04
205.34% 0.00% 0 2023-02-02 10:45:04
205.34% 0.00% 0 2023-02-02 10:30:03
205.34% 0.00% 0 2023-02-02 10:15:04
205.34% 0.00% 0 2023-02-02 10:00:04
205.34% 0.00% 0 2023-02-02 09:45:04
205.34% 0.00% 0 2023-02-02 09:30:04
205.34% 0.00% 0 2023-02-02 09:15:03
205.34% 0.00% 0 2023-02-02 09:00:04
205.34% 0.00% 0 2023-02-02 08:45:04
205.34% 0.00% 0 2023-02-02 08:30:04
205.34% 0.00% 0 2023-02-02 08:15:03
205.34% 0.00% 0 2023-02-02 08:00:04
205.34% -201.02% 90000 2023-02-01 17:45:03
205.34% -201.02% 90000 2023-02-01 17:30:04
205.34% -201.02% 90000 2023-02-01 17:15:04
205.34% -201.02% 90000 2023-02-01 17:00:04
205.34% -201.02% 90000 2023-02-01 16:45:03
205.34% -201.02% 90000 2023-02-01 16:30:05
205.34% -201.02% 90000 2023-02-01 16:15:04
πŸ‘οΈ0
81vette 81vette 1 year ago
book price 1.51,total cash 24M=1.71pps,i dont see how BPTS can fail?,low risk/insane high potential,fomo/greed should be high as kite
πŸ‘οΈ0
81vette 81vette 1 year ago
not in news yet ,market wire news is queuing it up now,hasn't even started to run without major news associated.
πŸ‘οΈ0
81vette 81vette 1 year ago
$20M traded so far,whats the saying lol
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock